4.00
+0.13(+3.36%)
Currency In USD
| Previous Close | 3.87 |
| Open | 3.95 |
| Day High | 4.1 |
| Day Low | 3.87 |
| 52-Week High | 13.68 |
| 52-Week Low | 3.01 |
| Volume | 144,282 |
| Average Volume | 850,416 |
| Market Cap | 255.23M |
| PE | -3.48 |
| EPS | -1.15 |
| Moving Average 50 Days | 6.49 |
| Moving Average 200 Days | 7.46 |
| Change | 0.13 |
If you invested $1000 in Larimar Therapeutics, Inc. (LRMR) 10 years ago, it would be worth $10.78 as of January 02, 2025 at a share price of $4. Whereas If you bought $1000 worth of Larimar Therapeutics, Inc. (LRMR) shares 5 years ago, it would be worth $300.3 as of January 02, 2025 at a share price of $4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia
GlobeNewswire Inc.
Dec 16, 2024 12:00 PM GMT
Daily subcutaneous injections of 25 mg nomlabofusp in 14 participants were generally well tolerated for up to 260 days in the ongoing open label extension (OLE) studyTissue frataxin (FXN) levels showed mean change from baseline of 1.32 pg/μg in bucca
Larimar Therapeutics Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024
GlobeNewswire Inc.
Nov 18, 2024 12:00 PM GMT
Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with Friedreich’s ataxia (FA)Modeling and simulation predict that, in most patients with FA, 50 mg of nomlabo
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
GlobeNewswire Inc.
Oct 30, 2024 11:00 AM GMT
Nomlabofusp program update expected mid-December to include available safety, pharmacokinetic (PK) and frataxin data, as well as available clinical outcomes observations from patients with Friedreich’s ataxia (FA) receiving 25 mg of nomlabofusp daily